Search

Your search keyword '"Andrews, Jane M."' showing total 121 results

Search Constraints

Start Over You searched for: Author "Andrews, Jane M." Remove constraint Author: "Andrews, Jane M." Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
121 results on '"Andrews, Jane M."'

Search Results

2. Reliability of Intestinal Ultrasound for Evaluating Crohn’s Disease Activity Using Point-of-care and Central Reading

3. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

5. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

8. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

9. A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies

11. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

15. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES

16. Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM

25. Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

27. Su1782 QUALITY, SAFETY AND EQUITY OF CARE OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS AT FOUR AUSTRALIAN TERTIARY REFERRAL CENTRES USING THE CLOUD-BASED MANAGEMENT SYSTEM CROHN'S COLITIS CARE (CCCARE) : A REAL WORLD OBSERVATIONAL STUDY

28. Su1733 BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

29. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

35. Sa1913 CONSENSUS GUIDELINES FOR THE REGULATION, PRODUCTION AND USE OF FECAL MICROBIOTA TRANSPLANTATION IN CLINICAL PRACTICE

40. Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)

48. Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD)

49. Sa1396 A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD)

50. 312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors

Catalog

Books, media, physical & digital resources